Necitumumab

From WikiProjectMed
Jump to navigation Jump to search
Necitumumab
Necitumumab EGFR 6B3S.png
Necitumumab Fab (blue) bound to EGFR (green). PDB: 6B3S​
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetEGFR
Names
Trade namesPortrazza
Clinical data
Main usesSquamous-cell cancer of the lung[1]
Side effectsRash, low magnesium[2]
Routes of
use		Intravenous infusion
Typical dose800 mg[2]
External links
AHFS/Drugs.comMonograph
US NLMNecitumumab
Legal
License data
Legal status
Pharmacokinetics
Elimination half-life~14 days
Chemical and physical data
FormulaC6436H9958N1702O2020S42
Molar mass144844.87 g·mol−1

Necitumumab, sold under the brand name Portrazza, is a medication used for non-small-cell lung carcinoma (NSCLC).[1] Specifically it is used, together with gemcitabine and cisplatin, for squamous-cell cancer of the lung that has spread.[1] Such use; however, is not recommended in the United Kingdom.[3] It is given by gradual injection into a vein.[2]

Common side effects include rash and low magnesium.[2] Other side effects may include cardiac arrest and blood clots.[2] Use in pregnancy may harm the baby.[2] It is a monoclonal antibody that binds to epidermal growth factor receptor (EGFR).[3]

Necitumumab was approved for medical use in the United States in 2015.[1] While it was approved for use in Europe in 2016, this approval was subsequently withdrawn.[4] In the United Kingdom it cost the NHS £1,450 per dose as of 2021.[3] This amount in the United States costs about 4,500 USD.[5]

Medical uses

It was counterproductive in non-squamous non-small-cell lung carcinoma.[6][7]

Dosage

The typical dose is 800 mg on day 1 and 8 out of 21 days.[2]

References

  1. ↑ 1.0 1.1 1.2 1.3 "Necitumumab Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 12 November 2021.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "DailyMed - PORTRAZZA- necitumumab solution". dailymed.nlm.nih.gov. Archived from the original on 9 August 2021. Retrieved 12 November 2021.
  3. ↑ 3.0 3.1 3.2 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 920. ISBN 978-0857114105.
  4. ↑ "Portrazza". Archived from the original on 7 August 2021. Retrieved 12 November 2021.
  5. ↑ "Portrazza Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 February 2021. Retrieved 12 November 2021.
  6. ↑ "Portrazza: Highlights of Prescribing Information" (PDF). www.accessdata.fda.gov. 2015. Archived (PDF) from the original on 2020-09-30. Retrieved 2019-09-28.
  7. ↑ Hand L (3 March 2015). "Necitumumab Fails in NSCLC". MedScape. Archived from the original on 2015-11-29. Retrieved 2015-11-25.

External links

Identifiers:
Stub icon

This monoclonal antibody–related article is a stub. You can help MDWiki by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help MDWiki by expanding it.

Retrieved from "https://mdwiki.org/w/index.php?title=Necitumumab&oldid=1290770"